Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense Suppression

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Keeling, Kim M ^a   Wang, Dan ^b,e   Dai, Yanying ^a   Murugesan, Srinivasan ^c   Chenna, Balachandra ^c   Clark, Jeremy ^c   Belakhov, Valery ^d   Kandasamy, Jeyakumar ^d   Velu, Sadanandan E ^c   Baasov, Timor ^d   Bedwell, David M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL COMPOUND; GENTAMICIN; GLYCOSAMINOGLYCAN; LEVO IDURONIDASE; MESSENGER RNA; NMDI 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GENE; GENE LOCUS; GENETIC CODE; GENETIC TRANSCRIPTION; HETEROZYGOTE; HURLER SYNDROME; IDUA GENE; IN VIVO STUDY; MOUSE; NONHUMAN; NONSENSE MEDIATED MRNA DECAY;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; MICE; MUCOPOLYSACCHARIDOSIS I; NONSENSE MEDIATED MRNA DECAY; RNA, MESSENGER;

EID: 84876059532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060478     Document Type: Article

References (56)

1. Keeling KM, Bedwell DM, (2011) Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA 2: 837-852.
2. Keeling KM, Wang D, Conard SE, Bedwell DM, (2012) Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol 47: 444-463.
3. Linde L, Kerem B, (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 24: 552-563.
4. Keeling KM, Bedwell DM (2010) Recoding therapies for genetic diseases. In: Atkins JF, Gesteland RF, editors. Recoding: Expansion of Decoding Rules Enriches Gene Expression. New York: Springer Publishing.
5. Clancy JP, Konstan MW, Rowe SMea (2006) A phase II study of PTC124 in CF patients harboring premature stop mutations. Ped Pulmonol Suppl 41: Abstract 269.
6. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719-727.
7. Sermet-Gaudelus I, Leal T, DeBoeck Cea, (2008) PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. J Cyst Fibros 7: S22.
8. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, et al. (2011) Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38: 59-69.
9. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67: 771-780.
10. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, et al. (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182: 1262-1272.
11. Wilschanski M, Armoni S, Yaacov Yea, (2008) PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. J Cyst Fibros 7: S22.
12. Konstan M, Accurso F, DeBoeck K, Kerem E, Rowe S, et al. (2012) Results of Phase 3 Study of Ataluren in Nonsense Mutation Cystic Fibrosis (nmCF). Abstracts of the European Cystic Fibrosis Conference 2012.
13. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, et al. (2007) Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117: 683-692.
14. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, et al. (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161: 860-865.
15. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349: 1433-1441.
16. Cheng Z, Muhlrad D, Lim MK, Parker R, Song H, (2007) Structural and functional insights into the human Upf1 helicase core. EMBO J 26: 253-264.
17. Weng Y, Czaplinski K, Peltz SW, (1996) Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein. Mol Cell Biol 16: 5477-5490.
18. Yamashita A, Ohnishi T, Kashima I, Taya Y, Ohno S, (2001) Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. Genes Dev 15: 2215-2228.
19. Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, et al. (2006) Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev 20: 355-367.
20. Cosson B, Couturier A, Chabelskaya S, Kiktev D, Inge-Vechtomov S, et al. (2002) Poly(A)-binding protein acts in translation termination via eukaryotic release factor 3 interaction and does not influence [PSI(+)] propagation. Mol Cell Biol 22: 3301-3315.
21. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, et al. (2003) Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. Mol Cell 12: 1187-1200.
22. Okada-Katsuhata Y, Yamashita A, Kutsuzawa K, Izumi N, Hirahara F, et al. (2011) N- and C-terminal Upf1 phosphorylations create binding platforms for SMG-6 and SMG-5:SMG-7 during NMD. Nucleic Acids Res 40: 1251-1266.
23. Usuki F, Yamashita A, Higuchi I, Ohnishi T, Shiraishi T, et al. (2004) Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann Neurol 55: 740-744.
24. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, et al. (2007) Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol 178: 1145-1160.
25. Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, et al. (2012) The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab 105: 116-125.
26. Wang D, Shukla C, Liu X, Schoeb TR, Clarke LA, et al. (2010) Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Mol Genet Metab 99: 62-71.
27. Brooks DA, Muller VJ, Hopwood JJ, (2006) Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 12: 367-373.
28. Menon KP, Neufeld EF, (1994) Evidence for degradation of mRNA encoding alpha-L-iduronidase in Hurler fibroblasts with premature termination alleles. Cell Mol Biol (Noisy-le-grand) 40: 999-1005.
29. Ashton LJ, Brooks DA, McCourt PA, Muller VJ, Clements PR, et al. (1992) Immunoquantification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Genet 50: 787-794.
30. Bunge S, Clements PR, Byers S, Kleijer WJ, Brooks DA, et al. (1998) Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta 1407: 249-256.
31. Pal M, Ishigaki Y, Nagy E, Maquat LE, (2001) Evidence that phosphorylation of human Upfl protein varies with intracellular location and is mediated by a wortmannin-sensitive and rapamycin-sensitive PI 3-kinase-related kinase signaling pathway. RNA 7: 5-15.
32. Boelz S, Neu-Yilik G, Gehring NH, Hentze MW, Kulozik AE, (2006) A chemiluminescence-based reporter system to monitor nonsense-mediated mRNA decay. Biochem Biophys Res Commun 349: 186-191.
33. Garbett NC, Graves DE, (2004) Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 4: 149-172.
34. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC, (2004) Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet 36: 1073-1078.
35. Vattem KM, Wek RC, (2004) Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A 101: 11269-11274.
36. Smith CM, Steitz JA, (1998) Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5′-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol 18: 6897-6909.
37. Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, et al. (2010) Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 18: 3735-3746.
38. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, et al. (2009) A gene network regulating lysosomal biogenesis and function. Science 325: 473-477.
39. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE, (2004) Nonsense-mediated decay approaches the clinic. Nat Genet 36: 801-808.
40. Khajavi M, Inoue K, Lupski JR, (2006) Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet 14: 1074-1081.
41. Wraith JE, (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 6: 489-506.
42. Mort M, Ivanov D, Cooper DN, Chuzhanova NA, (2008) A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat 29: 1037-1047.
43. McIlwain DR, Pan Q, Reilly PT, Elia AJ, McCracken S, et al. (2010) Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decay. Proc Natl Acad Sci U S A 107: 12186-12191.
44. Medghalchi SM, Frischmeyer PA, Mendell JT, Kelly AG, Lawler AM, et al. (2001) Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum Mol Genet 10: 99-105.
45. Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Monch K, Thoren LA, et al. (2008) NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev 22: 1381-1396.
46. Hwang J, Maquat LE, (2011) Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the question. Curr Opin Genet Dev 21: 422-430.
47. Wittmann J, Hol EM, Jack HM, (2006) hUPF2 Silencing Identifies Physiologic Substrates of Mammalian Nonsense-Mediated mRNA Decay. Mol Cell Biol 26: 1272-1287.
48. Isken O, Maquat LE, (2008) The multiple lives of NMD factors: balancing roles in gene and genome regulation. Nat Rev Genet 9: 699-712.
49. Frischmeyer-Guerrerio PA, Montgomery RA, Warren DS, Cooke SK, Lutz J, et al. (2011) Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc Natl Acad Sci U S A 108: 10638-10643.
50. Huang L, Lou CH, Chan W, Shum EY, Shao A, et al. (2011) RNA Homeostasis Governed by Cell Type-Specific and Branched Feedback Loops Acting on NMD. Mol Cell 43: 950-961.
51. Yepiskoposyan H, Aeschimann F, Nilsson D, Okoniewski M, Muhlemann O, (2011) Autoregulation of the nonsense-mediated mRNA decay pathway in human cells. RNA 17: 2108-2118.
52. Viegas MH, Gehring NH, Breit S, Hentze MW, Kulozik AE, (2007) The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway. Nucleic Acids Res 35: 4542-4551.
53. Seoighe C, Gehring C, (2010) Heritability in the efficiency of nonsense-mediated mRNA decay in humans. PLoS One 5: e11657.
54. Rivalle C, Ducrocq C, Lhoste J-M, Bisagni E, (1980) Photocyclization of 1-(1-chloroisoquinolin-6-yl)-1H-v-triazolo[4,5-c]pyridines to 10-chloro-5H-pyrido[3′4′:4,5]pyrrolo[isoquinolines (azaellipticines). J Org Chem 45: 2176-2180.
55. Rivalle C, Ducrocq C, Lhoste J-M, Wendling F, Bisagni E, Chermann J-C, (1981) 11H-Pyrido[3′,2′:4,5]pyrrolo[2,3-g]isoquinoleines (aza-7 ellipticines) substituees sur leur position 6. Tetrahedron 37: 2097-2103.
56. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.